Affinity Asset Advisors, LLC
Position in TERN — Terns Pharmaceuticals, Inc.
CIK 1773195
NEW YORK, NY
Position in TERN
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$0
+$0 QoQ
Shares Held
562,631
+2.3% QoQ
Ownership
0.487%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2022
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in TERN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Affinity Asset Advisors, LLC holds $1,842,784,374 across 87 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ROIV |
Roivant Sciences Ltd.
|
3,750,000 | $132,712,500 | |
| 2 | APGE |
Apogee Therapeutics, Inc.
|
987,000 | $131,004,510 | |
| 3 | SYRE |
Spyre Therapeutics, Inc.
|
1,279,134 | $113,561,516 | |
| 4 | XENE |
Xenon Pharmaceuticals Inc.
|
1,595,000 | $96,274,200 | |
| 5 | ERAS |
Erasca, Inc.
|
5,250,000 | $96,180,000 | |
| 6 | INSM |
INSMED Inc
|
650,000 | $69,303,000 | |
| 7 | PRAX |
Praxis Precision Medicines, Inc.
|
185,000 | $61,936,150 | |
| 8 | ORKA |
Oruka Therapeutics, Inc.
|
590,000 | $56,150,300 |
All Filings in TERN
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | — | 562,631 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | — | 550,000 | Shares | Sole | 2026-02-13 | |
| 2024-09-30 | — | 600,000 | Shares | Sole | 2024-11-13 | |
| 2024-03-31 | — | 450,000 | Shares | Sole | 2024-05-14 | |
| 2023-12-31 | — | 66,000 | Shares | Sole | 2024-02-13 | |
| 2023-09-30 | — | 325,000 | Shares | Sole | 2023-11-14 | |
| 2022-06-30 | — | 401,268 | Shares | Sole | 2022-08-12 | |
| No filing history on record for this holder in this stock. | ||||||